Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
Holding KYMR?
Track your performance easily
See the Price Targets and Ratings of:
KYMR Analyst Ratings
Strong Buy
12 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
KYMR Stock 12 Month Forecast
Average Price Target
$55.93
▲(21.64% Upside)
| Highest Price Target$74.00 | Average Price Target$55.93 | Lowest Price Target$38.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Wells Fargo
Reiterated
11/25/24
Stephens
Initiated
11/18/24
Morgan Stanley
Reiterated
11/06/24
Truist Financial
Reiterated
11/05/24
Guggenheim
Reiterated
11/01/24
TD Cowen
Assigned
11/01/24
H.C. Wainwright
Reiterated
11/01/24
B.Riley Financial
Reiterated
11/01/24
Stifel Nicolaus
Reiterated
11/01/24
Oppenheimer
$56
Buy
21.79%
Upside
Reiterated
11/01/24
Oppenheimer Keeps Their Buy Rating on Kymera Therapeutics (KYMR)
Leerink Partners
$60
Buy
30.49%
Upside
Reiterated
10/31/24
Analysts Conflicted on These Healthcare Names: IQVIA Holdings (NYSE: IQV), Halozyme (NASDAQ: HALO) and Kymera Therapeutics (NASDAQ: KYMR)
J.P. Morgan
$50→$60
Buy
30.49%
Upside
Reiterated
10/31/24
Analysts Conflicted on These Healthcare Names: Penumbra (NYSE: PEN), Kymera Therapeutics (NASDAQ: KYMR) and NovoCure (NASDAQ: NVCR)
Jefferies
$44→$59
Buy
28.32%
Upside
Reiterated
10/31/24
Kymera Therapeutics (KYMR) PT Raised to $59 at JefferiesJefferies analyst Kelly Shi raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $59.00 (from $44.00) while maintaining a Buy rating.
Piper Sandler
$56→$60
Buy
30.49%
Upside
Reiterated
09/25/24
Kymera Therapeutics (KYMR) PT Raised to $60 at Piper SandlerPiper Sandler analyst Edward Tenthoff raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $60.00 (from $56.00) while maintaining a Overweight rating.
Best Analysts Covering Kymera Therapeutics
Which Analyst Should I Follow If I Want to Buy KYMR and Sell After:
1 Month
xxx
Success Rate
5/8 ratings generated profit
Average Return
+11.61%
assigned a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +11.61% per trade.
3 Months
xxx
Success Rate
11/16 ratings generated profit
Average Return
+24.84%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +24.84% per trade.
1 Year
Success Rate
7/8 ratings generated profit
Average Return
+59.40%
assigned a buy rating 26 days ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +59.40% per trade.
2 Years
xxx
Success Rate
13/14 ratings generated profit
Average Return
+59.05%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 92.86% of your transactions generating a profit, with an average return of +59.05% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
KYMR Analyst Recommendation Trends
Rating
Jul 24
Aug 24
Sep 24
Oct 24
Nov 24
Strong Buy
4
3
0
0
2
Buy
10
13
13
14
14
Hold
6
7
7
4
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
20
23
20
18
19
Each month's total comprises the sum of three months' worth of ratings.
KYMR Financial Forecast
KYMR Stock Forecast FAQ
What is KYMR’s average 12-month price target, according to analysts?
Based on analyst ratings, Kymera Therapeutics’s 12-month average price target is $55.93.
What is KYMR’s upside potential, based on the analysts’ average price target?
Kymera Therapeutics has 21.64% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is KYMR a Buy, Sell or Hold?
Kymera Therapeutics has a consensus rating of Strong Buy which is based on 12 buy ratings, 3 hold ratings and 0 sell ratings.
What is Kymera Therapeutics’s price target?
The average price target for Kymera Therapeutics is $55.93. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $74.00 ,the lowest forecast is $38.00. The average price target represents 21.64% Increase from the current price of $45.98.
The highest analyst price target is $74.00 ,the lowest forecast is $38.00. The average price target represents 21.64% Increase from the current price of $45.98.
What do analysts say about Kymera Therapeutics?
Kymera Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of KYMR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.